Table 4.
Genotype results and treatment assignment among patients undergoing CYP2C19 testing.
| CYP2C19 Genotype* |
Total (%) | Race (number (%) | Aspirin + Clopidogrel |
Aspirin + Ticagrelor |
Aspirin + Prasugrel |
||
|---|---|---|---|---|---|---|---|
| African American |
European American |
Other (%) |
|||||
| *1/*1 | 91 (39.4) | 23 (37.1) | 67 (40.4) | 1 (33.3) | 63 | 28 | 0 |
| *1/*17 | 62 (26.8) | 14 (22.6) | 46 (27.7) | 2 (66.7) | 44 | 18 | 0 |
| *17/*17 | 14 (6.1) | 6 (9.7) | 8 (4.8) | 0 (0.0) | 8 | 6 | 0 |
| *1/*2 | 41 (17.7) | 10 (16.1) | 31 (18.7) | 0 (0.0) | 16 | 22 | 3 |
| *2/*17 | 16 (6.9) | 6 (9.7) | 10 (6.0) | 0 (0.0) | 8 | 7 | 1 |
| *2/*2 | 7 (3.0) | 3 (4.8) | 4 (2.4) | 0 (0.0) | 0 | 6 | 1 |
| TOTAL | 231 | 62 | 166 | 3 | 140 | 86 | 5 |
*
Genotype frequencies did not differ by race (all p-values>0.18)